Stock Update: Eli Lilly and Company (NYSE:LLY) – Lilly’s Depression Drug Fails to Meet Goals in Late-Stage Trials

[at Wall St. Cheat Sheet] – After failing to meet the company’s primary goals for the drug during three late-stage trials, Eli Lilly will cease the development of edivoxetine. Read more on this. . . . → Read More: Stock Update: Eli Lilly and Company (NYSE:LLY) – Lilly’s Depression Drug Fails to Meet Goals in Late-Stage Trials Similar posts: Company Update – AbbVie Inc. (NYSE:ABBV) – European drug trial secrecy case hit by delay Eli Lilly and Company (NYSE:LLY) ~ Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug